 | | Vol. 10.25 – 12 July, 2024 |
| |
|
|
| An integrated analysis of genes associated with metaplasia and dysplasia was conducted, verified, and characterized in the gastric tissues of patients by single-cell RNA sequencing. Scientists generated multiple mouse models to investigate the role of Klhl21 deletion in stemness, DNA damage, and tumor formation.
[Gut] |
|
|
|
 | | PUBLICATIONSRanked by the impact factor of the journal |
|
|
|
| Patients with locally advanced/metastatic HER2-positive gastric/gastroesophageal junction cancer and no prior systemic antitumor therapy were randomized 1:1:1 to 25 mg/kg HLX22 + HLX02 + oxaliplatin and capecitabine, 15 mg/kg HLX22 + HLX02 + XELOX, or placebo + HLX02 + XELOX in three-week cycles.
[Med] |
|
|
|
| LOC101928222 expression was upregulated in coloretal cancer (CRC) and was correlated with a worse outcome. Moreover, LOC101928222 was shown to promote migration, invasion, and angiogenesis in CRC.
[Journal of Experimental & Clinical Cancer Research] |
|
|
|
| Researchers demonstrated that a selective PI3Kδ inhibitor TYM-3–98 could suppress the AKT/mTOR signaling and activated the ferroptosis pathway in KRAS-mutant colorectal cancer cells in a concentration-dependent manner.
[Cell Death & Disease] |
|
|
|
| Investigators used a primary human intestinal epithelial cell (IEC) monolayer culture system with two engineered cell cycle reporters to directly measure cell cycle phases in freely cycling IECs by snapshot analysis of single images or by live imaging to directly quantify phase lengths.
[Scientific Reports] |
|
|
|
| RT-PCR and/or Western Blot analysis suggested that miR-513b-5p negatively affected STAT3 and Vimentin, while positively affecting E-cadherin expression in colon cancer cells.
[Discover Oncology] |
|
|
|
|
| The authors summarize the molecular signals and epigenetic mediators that orchestrate “fetal-like reversion” during intestinal regeneration.
[Cell Stem Cell] |
|
|
|
|
| Merus announced that the first patient has been dosed in the Company’s Phase II trial evaluating petosemtamab, a Biclonics® targeting EGFR and LGR5, in combination with standard chemotherapy in second line metastatic colorectal cancer.
[Merus] |
|
|
|
|
| August 23 – 28, 2024
Santa Cruz, California, United States |
|
|
|
|
|
| | City of Hope – Monrovia, California, United States |
|
|
|
| | University of Copenhagen – Copenhagen, Denmark |
|
|
|
| | Boston Medical Center – Boston, Massachusetts, United States |
|
|
|
| | Karolinska Institute – Solna, Sweden |
|
|
|
| | National Cancer Institute – Bethesda, Maryland, United States |
|
|
|
|
Cancer Stem Cell News
Cell Therapy News
Dermal Cell News
Endothelial Cell News
ESC & iPSC News
Extracellular Matrix News
Hematopoiesis News
Hepatic Cell News
Human Immunology News
Immune Regulation News
Intestinal Cell News
Mammary Cell News
Mesenchymal Cell News
Muscle Cell News
Neural Cell News
Organoid News
Pancreatic Cell News
Prostate Cell News
Pulmonary Cell News
